Long-Term (52-Week) Results Of a Phase 3, Randomized, Controlled Trial Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis and Current Skin Involvement (PALACE 3)

dc.contributor.author	BLANCO GARCIA, FRANCISCO JAVIER
dc.date.accessioned	2017-06-07T06:57:04Z
dc.date.available	2017-06-07T06:57:04Z
dc.date.issued	2013
dc.identifier.issn	0004-3591
dc.identifier.uri	http://hdl.handle.net/20.500.11940/915
dc.language.iso	eng
dc.title	Long-Term (52-Week) Results Of a Phase 3, Randomized, Controlled Trial Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis and Current Skin Involvement (PALACE 3)
dc.type	Publicación de congreso
dc.authorsophos	Edwards, C. J.
dc.authorsophos	Blanco, F. J.
dc.authorsophos	Crowley, J.
dc.authorsophos	Hu, C. C.
dc.authorsophos	Stevens, R. M.
dc.authorsophos	Birbara, C. A.
dc.identifier.isi	325359201310
dc.identifier.sophos	11583
dc.issue.number	Abstract 311
dc.journal.title	ARTHRITIS AND RHEUMATISM
dc.organization	Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña::INIBIC.- Instituto de Investigación Biomédica
dc.page.initial	S132
dc.page.final	S132
dc.rights.accessRights	openAccess
dc.typesophos	Comunicaciones a congresos
dc.volume.number	65

Files in this item

Files	Size	Format	View
There are no files associated with this item.